When Dr. Rick Bright with PATH visited MRIGlobal, he found a good fit to provide preclinical testing in support of PATH’s work to develop influenza vaccines that can be accessible and affordable for low-resource countries. Upon PATH’s award of the project to MRIGlobal, Dr. Bright specifically noted MRIGlobal’s “facility and laboratory capacity, the quality systems in place …and the leadership and commitment of the team.”

For this project, MRIGlobal is providing support to biotechnology companies that are developing candidate influenza vaccines in partnership with PATH. The work performed at MRIGlobal includes immunogenicity, toxicology, and virus challenge studies. These studies are designed to better understand the immune system, the overall safety of the vaccine, and the efficacy of the vaccine candidate to prevent infection following viral exposure.

PATH is an international, nonprofit organization that is working to help communities worldwide break longstanding cycles of poor health.